Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)

首圖

OSAKA, Japan & CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (「Takeda」) today announced that the data from the pivotal Phase 3 SOLSTICE......